Table II.

Expression of E-cadherin in clinicopathological features of breast cancer.

		E-cadherin expression, n
Clinicopathological factors	n	High expression	Low expression	High expression rate, %	χ2	P-value
Total patients	450	164	286	36.444
Age, years
≤35	87	40	47	45.977	8.373	0.015a
35–60	253	95	158	37.549
≥60	110	29	81	26.364
Number of positive lymph nodes No transfer	157	77	80	49.044	18.796	<0.001a
1–3	203	66	137	32.512
≥4	90	21	69	23.333
TNM staging
I	65	20	45	30.769	2.162	0.339
II	234	94	140	40.171
III	151	54	97	35.762
Breast mass size, cm
≤2	107	53	54	49.533	10.520	0.005a
2–5	274	90	184	32.847
≥5	69	21	48	30.435
Menopause
No	317	114	203	35.962	0.108	0.743
Yes	133	50	83	37.594
c-erbB-2
Positive	85	25	60	29.411	2.238	0.135
Negative	365	139	226	38.082
ER
Positive	167	44	123	26.347	11.688	<0.001a
Negative	283	120	163	42.403
Ki-67,%
≤14	41	20	21	48.780	2.964	0.085
>15	409	144	265	35.208
Molecular typing
Luminal A	62	22	40	35.484	17.466	<0.001a
Luminal B	249	84	165	33.735
HER-2-positive	47	30	17	63.830
Triple-negative	92	28	64	30.435
Histological grade
I	90	51	39	56.667	22.770	<0.001a
II	258	88	170	34.109
III	102	25	77	24.510

^aP<0.05. TNM, tumor-node-metastasis; c-erb-B2, receptor tyrosine-protein kinase erbB-2; ER, estrogen receptor; Ki-67, proliferation marker protein Ki-67; HER-2, human epidermal growth factor receptor 2.